Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. MicroPort CardioFlow Medtech's Revenue for the
six
months ended in Dec. 2025 was $25.10 Mil. MicroPort CardioFlow Medtech's average Accounts Receivable for the
six
months ended in Dec. 2025 was $49.92 Mil.
Hence, MicroPort CardioFlow Medtech's Receivables Turnover for the
six
months ended in Dec. 2025 was 0.50.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
MicroPort CardioFlow Medtech Receivables Turnover Related Terms
MicroPort CardioFlow Medtech Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MROPF vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, MicroPort CardioFlow Medtech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MicroPort CardioFlow Medtech Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MicroPort CardioFlow Medtech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where MicroPort CardioFlow Medtech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MicroPort CardioFlow Medtech (MROPF) has a Receivables Turnover of 0.50 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on MicroPort CardioFlow Medtech and its competitors. According to the industry distribution chart, MicroPort CardioFlow Medtech ranks #779 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 95.8%.
Is MicroPort CardioFlow Medtech's Receivables Turnover too high?
MicroPort CardioFlow Medtech's current Receivables Turnover is 0.50. The Medical Devices & Instruments industry median Receivables Turnover is 5.60. MicroPort CardioFlow Medtech's value of 0.50 is 91.1% below this industry median. Based on the distribution chart, MicroPort CardioFlow Medtech ranks #779 out of 813 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, MicroPort CardioFlow Medtech has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does MicroPort CardioFlow Medtech's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MicroPort CardioFlow Medtech ranks #779 out of 813 companies for Receivables Turnover. This places MicroPort CardioFlow Medtech in the lower half of its industry. The industry median Receivables Turnover is 5.60. MicroPort CardioFlow Medtech's value of 0.50 is 91.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.60, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MicroPort CardioFlow Medtech's current Receivables Turnover of 0.50 is 91.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on MicroPort CardioFlow Medtech and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MicroPort CardioFlow Medtech's current Receivables Turnover is 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MicroPort CardioFlow Medtech stock overvalued right now?
MicroPort CardioFlow Medtech (MROPF) has a current Receivables Turnover of 0.50. The stock's GF Value™ is $3.23, compared to a current price of $0.65 — trading 80% below its estimated fair value. The current Receivables Turnover is 0.50 and 91.1% below the Medical Devices & Instruments industry median of 5.60. MicroPort CardioFlow Medtech's overall GF Score™ is 59/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For MicroPort CardioFlow Medtech (MROPF), the current Receivables Turnover is 0.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MicroPort CardioFlow Medtech (MROPF) Overvalued in 2026?
Based on GuruFocus' analysis, MicroPort CardioFlow Medtech stock appears to be undervalued.
The current stock price of $0.65 is trading 80% below its estimated GF Value™ of $3.23.
Key valuation signals for MROPF:
Receivables Turnover: 0.50
GF Value™: $3.23 vs. price of $0.65 (80% below fair value)
Industry Position: 91.1% below the Medical Devices & Instruments median (#779 of 813)
No single metric tells the full story. See the MROPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of VitaFlow, VitaFlow Liberty, Angelguide and AnchorMan. The Group derives revenue from the sales of medical devices through appointed distributors. It derives maximum revenue from PRC.
59GF Score
Get the complete analysis for MROPF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MROPF has been successfully added to your 
